sellWeak cluster of 610b5-1 plan
Alexandra Balcom sold $721k of NUVL
Chief Financial Officer at Nuvalent, Inc.. 7,417 shares at an average of $97.25, traded Jan 5, 2026, filed Jan 7, 2026.
Warning score
38Value
$721k
7,417 shares
Holdings after
81,733
-8% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +21Trade size$721k at market
- 0Share of holdings soldSold 8.3% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-26-006569, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -871 | $96.06 | $84k | 88,279 | Jan 7, 2026 |
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,119 | $96.85 | $108k | 87,160 | Jan 7, 2026 |
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,929 | $97.96 | $189k | 85,231 | Jan 7, 2026 |
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -317 | $98.52 | $31k | 84,914 | Jan 7, 2026 |
| Jan 6, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,321 | $96.75 | $128k | 83,593 | Jan 7, 2026 |
| Jan 6, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,635 | $97.33 | $159k | 81,958 | Jan 7, 2026 |
| Jan 6, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -225 | $98.40 | $22k | 81,733 | Jan 7, 2026 |
| Jan 7, 2026 | AGrant or award Class A Common Stock10b5-1 | +17,500 | $0.00 | $0 | 99,233 | Jan 7, 2026 |
| Jan 7, 2026 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +17,500 | $0.00 | $0 | 17,500 | Jan 7, 2026 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $543k 5,500 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $2.5M 25,130 shares | -23% | |
| 30Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $3.4M 35,104 shares | -35% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.0M 30,000 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $567k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $567k 5,500 shares | -9% | |
| 7Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $561k 5,500 shares | -9% | |
| 18Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $1.7M 15,000 shares | -25% | |
| 35Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $676k 6,952 shares | -14% | |
| 36Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $721k 7,417 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.